Swedish Orphan Biovitrum AB (Sobi) has completed the issuance and repurchase of class C shares, a strategic financial move that underscores its commitment to fulfilling incentive obligations and reinforces its financial stability and reputation in t…

Swedish Orphan Biovitrum AB (SOBI) has authorized share repurchases and is expected to report strong financial growth, positioning the company for future success in the biotechnology sector.

Swedish Orphan Biovitrum AB (SOBI) reported a 3% increase in Q1 2025 revenue to SEK 6,465 million, driven by growth in its haematology segment.